Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014

Mary B. Daly; Robert Pilarski; Jennifer E. Axilbund; Saundra S. Buys; Beth Crawford; Susan Friedman; Judy E. Garber; Carolyn Horton; Virginia Kaklamani; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer Litton; Lisa Madlensky; P. Kelly Marcom; Sofia D. Merajver; Kenneth Offit; Tuya Pal; Boris Pasche; Gwen Reiser; Kristen Mahoney Shannon; Elizabeth Swisher; Nicoleta C. Voian; Jeffrey N. Weitzel; Alison Whelan; Georgia L. Wiesner; Mary A. Dwyer; Rashmi Kumar

doi:10.6004/jnccn.2014.0127

Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen ReiserKristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, Rashmi Kumar

Producción científica: Article › revisión exhaustiva

97 Citas (Scopus)

Resumen

During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/ or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/ PTEN hamartoma tumor syndrome.

Idioma original	English (US)
Páginas (desde-hasta)	1326-1338
Número de páginas	13
Publicación	JNCCN Journal of the National Comprehensive Cancer Network
Volumen	12
N.º	9
DOI	https://doi.org/10.6004/jnccn.2014.0127
Estado	Published - sept 1 2014
Publicado de forma externa	Sí

ASJC Scopus subject areas

Oncology

Acceder al documento

10.6004/jnccn.2014.0127

Otros archivos y enlaces

Citar esto

Daly, M. B., Pilarski, R., Axilbund, J. E., Buys, S. S., Crawford, B., Friedman, S., Garber, J. E., Horton, C., Kaklamani, V., Klein, C., Kohlmann, W., Kurian, A., Litton, J., Madlensky, L., Marcom, P. K., Merajver, S. D., Offit, K., Pal, T., Pasche, B., ... Kumar, R. (2014). Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014. JNCCN Journal of the National Comprehensive Cancer Network, 12(9), 1326-1338. https://doi.org/10.6004/jnccn.2014.0127

Daly, MB, Pilarski, R, Axilbund, JE, Buys, SS, Crawford, B, Friedman, S, Garber, JE, Horton, C, Kaklamani, V, Klein, C, Kohlmann, W, Kurian, A, Litton, J, Madlensky, L, Marcom, PK, Merajver, SD, Offit, K, Pal, T, Pasche, B, Reiser, G, Shannon, KM, Swisher, E, Voian, NC, Weitzel, JN, Whelan, A, Wiesner, GL, Dwyer, MA & Kumar, R 2014, 'Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, n.º 9, pp. 1326-1338. https://doi.org/10.6004/jnccn.2014.0127

@article{5d4b59253d024baa9edf184fd9c66098,

title = "Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014",

abstract = "During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/ or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/ PTEN hamartoma tumor syndrome.",

author = "Daly, {Mary B.} and Robert Pilarski and Axilbund, {Jennifer E.} and Buys, {Saundra S.} and Beth Crawford and Susan Friedman and Garber, {Judy E.} and Carolyn Horton and Virginia Kaklamani and Catherine Klein and Wendy Kohlmann and Allison Kurian and Jennifer Litton and Lisa Madlensky and Marcom, {P. Kelly} and Merajver, {Sofia D.} and Kenneth Offit and Tuya Pal and Boris Pasche and Gwen Reiser and Shannon, {Kristen Mahoney} and Elizabeth Swisher and Voian, {Nicoleta C.} and Weitzel, {Jeffrey N.} and Alison Whelan and Wiesner, {Georgia L.} and Dwyer, {Mary A.} and Rashmi Kumar",

year = "2014",

month = sep,

day = "1",

doi = "10.6004/jnccn.2014.0127",

language = "English (US)",

volume = "12",

pages = "1326--1338",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "9",

}

TY - JOUR

T1 - Genetic/familial high-risk assessment

T2 - Breast and ovarian, version 1.2014

AU - Daly, Mary B.

AU - Pilarski, Robert

AU - Axilbund, Jennifer E.

AU - Buys, Saundra S.

AU - Crawford, Beth

AU - Friedman, Susan

AU - Garber, Judy E.

AU - Horton, Carolyn

AU - Kaklamani, Virginia

AU - Klein, Catherine

AU - Kohlmann, Wendy

AU - Kurian, Allison

AU - Litton, Jennifer

AU - Madlensky, Lisa

AU - Marcom, P. Kelly

AU - Merajver, Sofia D.

AU - Offit, Kenneth

AU - Pal, Tuya

AU - Pasche, Boris

AU - Reiser, Gwen

AU - Shannon, Kristen Mahoney

AU - Swisher, Elizabeth

AU - Voian, Nicoleta C.

AU - Weitzel, Jeffrey N.

AU - Whelan, Alison

AU - Wiesner, Georgia L.

AU - Dwyer, Mary A.

AU - Kumar, Rashmi

PY - 2014/9/1

Y1 - 2014/9/1

N2 - During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/ or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/ PTEN hamartoma tumor syndrome.

AB - During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/ or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/ PTEN hamartoma tumor syndrome.

UR - http://www.scopus.com/inward/record.url?scp=84907298200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907298200&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0127

DO - 10.6004/jnccn.2014.0127

M3 - Article

C2 - 25190698

AN - SCOPUS:84907298200

SN - 1540-1405

VL - 12

SP - 1326

EP - 1338

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto